ImmunoGen Inc (NASDAQ:IMGN)

11.27
Delayed Data
As of Feb 16
 +0.62 / +5.82%
Today’s Change
2.40
Today|||52-Week Range
11.61
+75.82%
Year-to-Date
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
Feb 14 / Zacks.com - Paid Partner Content
ImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/Y
Feb 09 / Zacks.com - Paid Partner Content
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
Feb 12 / Zacks.com - Paid Partner Content
Is a Surprise Coming for ImmunoGen (IMGN) This Earnings Season?
Feb 08 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close10.65
Today’s open10.70
Day’s range10.45 - 11.61
Volume4,188,820
Average volume (3 months)3,175,711
Market cap$1.5B
Data as of 4:00pm ET, 02/16/2018

Growth & Valuation

Earnings growth (last year)+45.86%
Earnings growth (this year)--
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+168.41%
P/E ratioNM
Price/Sales5.45
Price/Book--

Competitors

 Today’s
change
Today’s
% change
CHRSCoherus BioSciences ...-0.15-1.55%
NTLAIntellia Therapeutic...-0.57-2.23%
MYOVMyovant Sciences Ltd+0.10+0.68%
CRSPCRISPR Therapeutics ...-0.61-1.50%
Data as of 4:02pm ET, 02/16/2018

Financials

Last reporting dateFebruary 9, 2018
EPS forecast (this quarter)-$0.08
Annual revenue (last year)$115.4M
Annual profit (last year)-$96.0M
Net profit margin-83.17%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark J. Enyedy
Chief Financial Officer &
Executive Vice President
David B. Johnston
Corporate headquarters
Waltham, Massachusetts

Forecasts